Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan · Delayed Price · Currency is TWD 7.97
-0.05 (-0.62%)
Sep 5, 2025, 1:52 PM CST
Mercury Biopharmaceutical Revenue
Mercury Biopharmaceutical had revenue of 246.00K TWD in the half year ending December 31, 2024, a decrease of -90.82%. This brings the company's revenue in the last twelve months to 246.00K, down -95.72% year-over-year. In the year 2024, Mercury Biopharmaceutical had annual revenue of 4.96M with 380.45% growth.
Revenue (ttm)
246.00K
Revenue Growth
-95.72%
P/S Ratio
13,667.13
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.96M | 3.93M | 380.45% |
| Dec 31, 2023 | 1.03M | -1.65M | -61.46% |
| Dec 31, 2022 | 2.68M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.83M |
| PharmaEssentia | 12.63B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Lumosa Therapeutics | 37.25M |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Center Laboratories | 1.60B |